Literature DB >> 19931195

Pharmacogenetic profiling in the treatment of heart disease.

Gerald W Dorn1.   

Abstract

Pharmacogenetics is the study of gene-drug interactions. In the post-Human Genome era, and with the realization that personal genotypes differ by millions of bases (gene polymorphisms), the application of genetics to explain interindividual differences in clinical drug response seems to offer great promise. Here, recent basic and translational developments in pharmacogenetic profiling of beta-blocker response in heart failure are reviewed in the context of the possible consequences of such advances on drug development and clinical therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931195      PMCID: PMC2811068          DOI: 10.1016/j.trsl.2009.07.010

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  42 in total

1.  Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.

Authors:  S Raimundo; J Fischer; M Eichelbaum; E U Griese; M Schwab; U M Zanger
Journal:  Pharmacogenetics       Date:  2000-10

2.  Clopidogrel and the concept of high-risk pharmacokinetics.

Authors:  Dan M Roden; C Michael Stein
Journal:  Circulation       Date:  2009-04-28       Impact factor: 29.690

3.  The mechanistic imperative for pharmacogenomics.

Authors:  Gerald W Dorn; Sharon Cresci
Journal:  Pharmacogenomics       Date:  2008-07       Impact factor: 2.533

Review 4.  Clinical pharmacokinetics of metoprolol.

Authors:  C G Regårdh; G Johnsson
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

5.  Beta-blockers in congestive heart failure. A Bayesian meta-analysis.

Authors:  J M Brophy; L Joseph; J L Rouleau
Journal:  Ann Intern Med       Date:  2001-04-03       Impact factor: 25.391

6.  Clinical and genetic modifiers of long-term survival in heart failure.

Authors:  Sharon Cresci; Reagan J Kelly; Thomas P Cappola; Abhinav Diwan; Daniel Dries; Sharon L R Kardia; Gerald W Dorn
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

7.  Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.

Authors:  M J Bijl; L E Visser; R H N van Schaik; J A Kors; J C M Witteman; A Hofman; A G Vulto; T van Gelder; B H Ch Stricker
Journal:  Clin Pharmacol Ther       Date:  2008-09-10       Impact factor: 6.875

8.  Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.

Authors:  T Rau; H Wuttke; L M Michels; U Werner; K Bergmann; M Kreft; M F Fromm; T Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2008-11-26       Impact factor: 6.875

9.  CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.

Authors:  C F Sharp; S J Gardiner; B P Jensen; R L Roberts; R W Troughton; J G Lainchbury; E J Begg
Journal:  Pharmacogenomics J       Date:  2009-04-14       Impact factor: 3.550

10.  CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.

Authors:  Ksenia Goryachkina; Aleksandra Burbello; Svetlana Boldueva; Svetlana Babak; Ulf Bergman; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2008-07-22       Impact factor: 2.953

View more
  4 in total

1.  G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers.

Authors:  Mihai V Podgoreanu; Joseph P Mathew; Miklos D Kertai; Yen-Wei Li; Yi-Ju Li; Svati H Shah; William E Kraus; Manuel L Fontes; Mark Stafford-Smith; Mark F Newman
Journal:  Circ Cardiovasc Genet       Date:  2014-07-21

2.  Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving β-blockers.

Authors:  Miklos D Kertai; Wenjing Qi; Yi-Ju Li; Frederick W Lombard; Yutao Liu; Michael P Smith; Mark Stafford-Smith; Mark F Newman; Carmelo A Milano; Joseph P Mathew; Mihai V Podgoreanu
Journal:  J Mol Cell Cardiol       Date:  2016-02-06       Impact factor: 5.000

Review 3.  Heart failure: advances through genomics.

Authors:  Esther E Creemers; Arthur A Wilde; Yigal M Pinto
Journal:  Nat Rev Genet       Date:  2011-03-22       Impact factor: 53.242

Review 4.  Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.